Cargando…
THER-06. GENOMIC AND IMMUNE CHARACTERIZATION OF TRIPLE NEGATIVE BREAST CANCER BRAIN METASTASES
INTRODUCTION: Approximately 50% of patients with metastatic triple negative breast cancer (TNBC) will develop brain metastases (BM). Routinely treated with radiotherapy and/or surgery, survival is generally less than one year. There are no approved systemic therapies to treat TNBC BM. We characteriz...
Autores principales: | Vincent, Benjamin, Sambade, Maria, Chai, Shengjie, Siegel, Marni, Cuaboy, Luz, Holye, Alan, Parker, Joel, Perou, Charles, Anders, Carey |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213186/ http://dx.doi.org/10.1093/noajnl/vdz014.049 |
Ejemplares similares
-
BSCI-06 COMPREHENSIVE ANALYSIS OF THE IMMUNOGENOMICS OF TRIPLE NEGATIVE BREAST CANCER BRAIN METASTASES FROM LCCC1419
por: Van Swearingen, Amanda, et al.
Publicado: (2022) -
Comprehensive Analysis of the Immunogenomics of Triple-Negative Breast Cancer Brain Metastases From LCCC1419
por: Routh, Eric D., et al.
Publicado: (2022) -
Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer
por: Anders, Carey K, et al.
Publicado: (2022) -
THER-15. DEVELOPING TUMOR-HOMING CYTOTOXIC HUMAN INDUCED NEURAL STEM CELL THERAPY FOR BRAIN METASTASES
por: Mercer-Smith, Alison, et al.
Publicado: (2019) -
Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine models
por: Sambade, Maria J, et al.
Publicado: (2019)